日本語 >>
TOP page
Journal
Presentation
(Last updated : 2021-01-21 10:02:16)
藤田 俊一
Department
,
Position
■
Journal
1.
2021/01
Certolizumab pegol-induced immunoglobulin A vasculitis in a patient with rheumatoid arthritis
2.
2020/11/21
A tiger man: a case of muscular sarcoidosis
3.
2020/09/23
Tattoo skin reaction as a skin manifestation of systemic sarcoidosis
4.
2020/07/10
Severe oral stomatitis due to reactivation of herpes simplex virus type 1 in a methotrexate-treated patient with dermatomyositis.
5.
2020/06/10
Effect of Angiotensin II on Bone Erosion and Systemic Bone Loss in Mice with Tumor Necrosis Factor-Mediated Arthritis
6.
2019/10/31
Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should be Treated with Low-dose Prednisolone During Pembrolizumab Therapy
7.
2019/07
Tuberculous fasciitis in a patient with systemic lupus erythematosus.
8.
2019/05
Infection of Helicobacter cinaedi Should be Treated for an Adequate Duration with Combined Antibiotic Therapy: Author's Reply.
9.
2019/03
Japanese Spotted Fever: A Rare Cause of Arthritis
10.
2019/02/22
Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.
11.
2019/01
Complete resolution of giant cell arteritis after tocilizumab monotherapy determined by positron emission tomography-CT
12.
2018/12
Bacteremia possibly caused by Helicobacter cinaedi and associated with painful erythema in rheumatoid arthritis with malignant lymphoma
13.
2018/10
Bladder carcinoma in situ in a patient with lupus cystitis
14.
2018/03
IgG4-related autoimmune pancreatitis complicated by splenic artery pseudoaneurysm.
15.
2018/03
Treatment of refractory rheumatoid pleural effusion with abatacept.
16.
2018/01
Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastogenesis.
17.
2015/04
Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis
18.
2014/07
ACT-Ray study
Display 5 items
Display all(18)
■
Presentation
1.
2020/10/24
Edit Effect of Angiotensin II on Bone Erosion and Systemic Bone Loss in Mice with Tumor Necrosis Factor-Mediated Arthritis
2.
2019/04/17
SH3BP2 gain-of-function mutation ameliorates lupus in B6.MRL-Faslpr mice
3.
2018/04/27
Bone systemic administration of angiotensin II and its type 1 receptor gene deletion exacerbates erosive bone destruction in hTNF-transgenic arthritis mice
4.
2018/04/27
Myostatin inhibition reduces bone loss in an unloading osteoporosis model
5.
2018/04/27
Pharmacological inhibition of tankyrase induces bone loss in mice by increasing osteoclastgenesis
6.
2018/04/27
SH3BP2 gain-of-function mutation alleviates lupus phenotypes in B6.MRL-Faslpr mice
7.
2018/04/26
Functional analysis of the novel G58V mutation in the TNFRSF1A gene identified in a family with TNF receptor-associated periodic syndrome(TRAPS)
8.
2017/11/07
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
9.
2017/11/06
Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction ofhTNF-Transgenic Arthritis Mice
10.
2017/11/05
Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
11.
2017/11/05
Tankyrase/Wnt Inhibitor Upregulates Osteoclastogenesis and Osteoblastogenesis Via
SH3BP2
12.
2017/11/05
The Effect of Myostatin Inhibition on Bone Loss in Murine Osteoporosis Models
13.
2017/04/21
Tankyrase regulates bone mass and osteoclastogenesis
14.
2017/04/20
Angiotensin II exacerbates bone destruction in human TNF-transgenic arthritis mice
15.
2017/04/20
The effect of myostatin inhibition on bone loss in murine osteoporosis models
16.
2016/11/14
Tankyrase Regulates Osteoclastogenesis Via SH3BP2
17.
2016/11/13
Angiotensin II Exacerbates Bone Destruction in TNF-Transgenic Arthritis Mice
18.
2016/04/23
Tankyrase Inhibitor Promotes Osteoclastogenesis by Enhancing SH3BP2 expression
19.
2015/11/16
Tankyrase regulates osteoclastogenesis via SH3BP2 expression
20.
2012/05/09
Biological agents for rheumatoid arthritis (RA) after the short term remission of methotrexate-associated lymphoproliferative disorders (MTX-LPD)
Display 5 items
Display all(20)